15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
View Patent ↗The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM 197 . The immunogenic composition, preferably formulated as a vaccine on an aluminum -based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.
1. An immunogenic composition comprising:
(1) a multivalent polysaccharide-protein conjugate mixture having capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F of Streptococcus pneumoniae conjugated to CRM 197 and no other S. pneumoniae polysaccharide protein conjugates from a different serotype; and
(2) a pharmaceutically acceptable carrier.
2. The immunogenic composition of claim 1 , further comprising an adjuvant.
3. The immunogenic composition claim 2 , wherein the adjuvant is an aluminum-based adjuvant.
4. The immunogenic composition of claim 3 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
5. The immunogenic composition of claim 4 , wherein the adjuvant is aluminum phosphate.
6. A method of inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide, comprising administering to a human an immunologically effective amount of the immunogenic composition of claim 1 .
7. The method of claim 6 , wherein the immunogenic composition administered is a single 0.5 mL dose formulated to contain: 2 μg of each saccharide, except for 6B at 4 μg; about 32 μg CRM 197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; 150 mM sodium chloride and 20 mM L-histidine buffer.